TrialPath
High blood pressure · Washington

High blood pressure clinical trials in Washington

9 recruiting hypertension studies within range of Washington. Click any trial for full eligibility criteria and contact info.

Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry

NCT04669548 · Intraabdominal Hypertension, Abdominal Compartment Syndrome, Acute Kidney Injury
Recruiting

The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.

Phase—
TypeObservational
Age18 Years
WhereLos Angeles, California, United States + 8 more
SponsorPotrero Medical
▾Tap for details
Apply

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

Recruiting

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

PhasePhase 3
TypeInterventional
Age18 Years
WhereFairhope, Alabama, United States + 770 more
SponsorAstraZeneca
▾Tap for details
Apply

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

NCT06526195 · Heart Failure, Heart Diseases, Cardiovascular Diseases
Recruiting

The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.

PhaseNA
TypeInterventional
Age18 Years
WherePhoenix, Arizona, United States + 69 more
SponsorAbbott Medical Devices
▾Tap for details
Apply

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Recruiting

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 24 more
SponsorAllRock Bio, Inc.
▾Tap for details

Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Recruiting

The primary objectives of the study are to evaluate the safety and tolerability, and pharmacokinetics (PK) of sotatercept over 24 weeks of treatment in children ≥1 to \<18 years of age with PAH World Health Organization (WHO) Group 1 on standard of care (SoC). There is no formal hypothesis.

PhasePhase 2
TypeInterventional
Age1 Year – 17 Years
WhereLos Angeles, California, United States + 34 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply

Non-invasive Central Venous Pressure Estimation in Pediatric Patients

NCT06885073 · Central Venous Pressure
Recruiting

Central Venous Pressure (CVP) is a standard parameter for hemodynamic monitoring and is currently measured through the insertion of a catheter. The pediatric population is especially vulnerable to risks associated to this invasive procedure, including infection, thrombosis, and pneumothorax. The proposed pilot study will evaluate safety and preliminary efficacy of a new non-invasive ultrasound-based venous occlusion pressure (VOP) monitoring device (CPMX2) in children equipped with an invasive catheter for CVP monitoring as part of standard of care.

PhaseNA
TypeInterventional
Age21 Years
WhereWashington D.C., District of Columbia, United States
SponsorCompremium AG
▾Tap for details
Apply

A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease

Recruiting

The goal of this clinical study is to evaluate the safety and efficacy of percutaneous pulmonary artery denervation with the Multi-Pole Pulmonary Artery Radiofrequency Ablation Enhancor System in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH) associated with left heart disease (LHD). This randomized control trial will compare the investigational device (The Enhancor System) to control (medical therapy.) Participants who will consist of patients with chronic heart failure (HF) who are receiving maximally tolerated guideline-directed medical therapy (GDMT) for left heart failure, are clinically stable, and who have been diagnosed with CpcPH by right heart catheterization (RHC), will be treated with PADN and followed for 3 years.

PhaseNA
TypeInterventional
Age18 Years – 85 Years
WhereTucson, Arizona, United States + 18 more
SponsorPulnovo Medical, Inc.
▾Tap for details
Apply

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Recruiting

This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 70 more
SponsorUnited Therapeutics
▾Tap for details
Apply

Natural History of Sickle Cell Disease

NCT00081523 · Pain Crisis
Recruiting

This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated. Subjects will receive their general medical care outside the NIH and will be seen at our clinic or at CNHS with varying frequency. Subjects may be seen for multiple visits. Subjects may be asked to return for additional testing as needed. Clinical care for patients with sickle cell disease will be provided as appropriate through the Sickle Cell Clinic and the inpatient clinical center.

Phase—
TypeObservational
Age2 Years – 90 Years
WhereWashington D.C., District of Columbia, United States + 2 more
SponsorNational Heart, Lung, and Blood Institute (NHLBI)
▾Tap for details
Apply